SEC Form 4
ResMed Inc. (RMD) insider trading
In the 12 months to Oct 24, 2026, 5 RMD insiders reported open-market sales of $22.3M across 31 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $22.3M
- 31 filings · 5 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 31 of 31
- All $22.3M sold was pre-arranged
Who traded RMD, and when
- Sale
- Sale, pre-arranged (10b5-1)
RMD daily close from Oct 24, 2025 to Oct 23, 2026, between $182.82 and $275.96, last $252.86. 31 sale and 0 purchase filings by 5 insiders, marked at their filing dates. Michael J. Farrell, Chairman and CEO: sold $14.6M across 12 filings, first filed Nov 10, 2025, last Oct 8, 2026. Peter C. Farrell, Director: sold $5.0M across 8 filings, first filed Nov 13, 2025, last Sep 4, 2026. Brett Sandercock, Chief Financial Officer: sold $2.0M across 6 filings, first filed Nov 4, 2025, last Apr 3, 2026. Witte Jan De, Director: sold $645.9K across 2 filings, first filed Nov 13, 2025, last Nov 26, 2025. Michael J. Rider, Global General Counsel: sold $37.3K across 3 filings, first filed Dec 2, 2025, last Feb 6, 2026.
Largest mark · tap a row for others
Michael J. Farrell · Chairman and CEO
Sale $2,000,773
8,011 shares at $249.75 avg
Filed Nov 10, 2025 · traded Nov 7
Pre-arranged (10b5-1) · close on filing date $250.10
Michael J. Farrell · Chairman and CEO
Chairman and CEO
$14.6M soldPeter C. Farrell · Director
Director
$5.0M soldBrett Sandercock · Chief Financial Officer
Chief Financial Officer
$2.0M soldWitte Jan De · Director
Director
$645.9K soldMichael J. Rider · Global General Counsel
Global General Counsel
$37.3K soldHas ResMed Inc.'s CEO sold stock?
Yes. Michael J. Farrell (CEO) sold 62,912 shares ($14.6M) between Nov 2025 and Oct 2026, all under a pre-arranged 10b5-1 plan.
Open-market trades
31 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Michael J. Farrell | Chairman and CEO | $14.6M | — | 12 | 100% of sales | |
| Peter C. Farrell | Director | $5.0M | — | 8 | 100% of sales | |
| Brett Sandercock | Chief Financial Officer | $2.0M | — | 6 | 100% of sales | |
| Witte Jan De | Director | $645.9K | — | 2 | 100% of sales | |
| Michael J. Rider | Global General Counsel | $37.3K | — | 3 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 4,991 | $226.33 | $1.1M | 479,803 | |
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 4,991 | $222.44 | $1.1M | 466,256 | |
traded | Peter C. Farrell Director | SalePre-arranged (10b5-1) | 970 | $234.73 | $227.7K | 51,803 | |
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 4,991 | $205.69 | $1.0M | 466,256 | |
traded | Peter C. Farrell Director | SalePre-arranged (10b5-1) | 8,000 | $225.00 | $1.8M | 52,773 | |
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 4,991 | $218.55 | $1.1M | 466,223 | |
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 4,991 | $193.96 | $968.1K | 466,256 | |
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 4,991 | $207.82 | $1.0M | 466,223 | |
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 4,991 | $225.50 | $1.1M | 466,223 | |
traded | Brett Sandercock Chief Financial Officer | SalePre-arranged (10b5-1) | 1,000 | $224.31 | $224.3K | 83,495 | |
traded | Peter C. Farrell Director | SalePre-arranged (10b5-1) | 2,000 | $225.00 | $450.0K | 60,773 | |
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 4,991 | $251.03 | $1.3M | 466,223 | |
traded | Peter C. Farrell Director | SalePre-arranged (10b5-1) | 2,000 | $260.22 | $520.4K | 62,773 | |
traded | Brett Sandercock Chief Financial Officer | SalePre-arranged (10b5-1) | 1,000 | $254.30 | $254.3K | 84,495 | |
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 4,991 | $273.78 | $1.4M | 466,223 | |
traded | Michael J. Rider Global General Counsel | SalePre-arranged (10b5-1) | 50 | $260.00 | $13.0K | 9,691 | |
traded | Peter C. Farrell Director | SalePre-arranged (10b5-1) | 2,000 | $251.31 | $502.6K | 64,773 | |
traded | Brett Sandercock Chief Financial Officer | SalePre-arranged (10b5-1) | 1,000 | $257.03 | $257.0K | 85,495 | |
traded | Peter C. Farrell Director | SalePre-arranged (10b5-1) | 2,000 | $248.83 | $497.7K | 66,773 | |
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 4,991 | $248.46 | $1.2M | 466,223 | |
traded | Michael J. Rider Global General Counsel | SalePre-arranged (10b5-1) | 50 | $241.75 | $12.1K | 9,741 | |
traded | Brett Sandercock Chief Financial Officer | SalePre-arranged (10b5-1) | 1,000 | $241.75 | $241.8K | 86,495 | |
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 4,991 | $251.41 | $1.3M | 466,223 | |
traded | Peter C. Farrell Director | SalePre-arranged (10b5-1) | 2,000 | $251.47 | $502.9K | 68,773 | |
traded | Brett Sandercock Chief Financial Officer | SalePre-arranged (10b5-1) | 1,000 | $244.16 | $244.2K | 87,495 | |
traded | Michael J. Rider Global General Counsel | SalePre-arranged (10b5-1) | 50 | $244.16 | $12.2K | 9,791 | |
traded | Witte Jan De Director | SalePre-arranged (10b5-1) | 2,055 | $255.00 | $524.0K | 4,261 | |
traded | Witte Jan De Director | SalePre-arranged (10b5-1) | 487 | $250.25 | $121.9K | 5,319 | |
traded | Peter C. Farrell Director | SalePre-arranged (10b5-1) | 2,000 | $252.05 | $504.1K | 66,110 | |
traded | Michael J. Farrell Chairman and CEO | SalePre-arranged (10b5-1) | 8,011 | $249.75 | $2.0M | 467,866 | |
traded | Brett Sandercock Chief Financial Officer | SalePre-arranged (10b5-1) | 3,000 | $247.54 | $742.6K | 85,745 |
GET /stocks/filings/vX/form-4?tickers=RMD&filing_date.gte=2025-10-24&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"RMD"
],
"issuer_cik": "0000943819",
"owner_cik": "0001485164",
"accession_number": "0000943819-26-000085",
"form_type": "4",
"filing_date": "2026-10-08",
"period_of_report": "2026-10-07",
"issuer_name": "RESMED INC",
"issuer_trading_symbol": "RMD",
"owner_name": "Farrell Michael J.",
"is_director": true,
"is_officer": true,
"officer_title": "Chairman and CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "ResMed Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-07",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4991,
"transaction_price_per_share": 226.3349,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 479803,
"transaction_value": 1129637.4859,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024."
},
{
"id": "F2",
"description": "This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price."
}
]
},
{
"tickers": [
"RMD"
],
"issuer_cik": "0000943819",
"owner_cik": "0001485164",
"accession_number": "0000943819-26-000052",
"form_type": "4",
"filing_date": "2026-09-10",
"period_of_report": "2026-09-08",
"issuer_name": "RESMED INC",
"issuer_trading_symbol": "RMD",
"owner_name": "Farrell Michael J.",
"is_director": true,
"is_officer": true,
"officer_title": "Chairman and CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "ResMed Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-09-08",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 4991,
"transaction_price_per_share": 222.4385,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 466256,
"transaction_value": 1110190.5535,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024."
},
{
"id": "F2",
"description": "This transaction was executed in multiple trades at prices ranging from $220.680 - $225.390. The price reported above reflects the weighted average sale price."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 45 records
- Option exercises15 records
- Tax withholding13 records
- Grants and awards17 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
Build this yourself
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for RMD every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.